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intoxication in an elderly patient with
bipolar I disorderDear Editor,
A 67-year-old female patient with bipolar I disorder had
been taking the medications lithium (900 mg daily) and
quetiapine (600 mg daily) for 6 months. She unfortunately
presented with confused consciousness, tremor of the four
limbs, and diarrhea 3 days before visiting our emergency
department. In the emergency department, the patient’s
body temperature was 38.9C. The serum levels of lithium
and creatinine were elevated at 3.18 mmol/L and 1.82 mg/
dL, respectively. The patient’s bilateral pupil size, blood
pressure, electrocardiography, and oxygen saturation were
normal. A lumbar puncture revealed normal results. Mag-
netic resonance imaging of the brain showed a symmetrical
high signal intense lesion in the splenium of the corpus
callosum on the three-direction diffusion image, which was
consistent with axonal injury. There was no evidence of
stroke, structural lesions, encephalitis, hepatic encepha-
lopathy, blood sugar abnormality, and hypoxia of the brain,
based on the magnetic resonance imaging evaluation. The
fever subsided in 2 days. On the 3rd day after hospitaliza-
tion, the levels of lithium (0.77 mmol/L) and creatinine
(0.61 mg/dL) returned to within their normal ranges. The
delirium unfortunately persisted and the patient developed
involuntary movements such as biting and mouth chewing,
and rapid, purposeless, irregular, and spontaneous choreic
movements of her arms, wrists, and hands. Foot squirming
and twisting of neck and shoulder were also noted. The
involuntary movements subsided when sleeping.
We restored quetiapine monotherapy for her bipolar
disorder. One month later, the delirium resolved and she
could reply with simple words. However, the patient still
had ataxia, dysarthria, and involuntary movement. Owing
to severe involuntary movements, we added amantadineConflicts of interest: The author declares no conflicts of
interest.
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haloperidol, 0.25 mg three times daily. Four weeks after
prescribing medications (the baseline time point), the pa-
tient was able to try an oral diet. Six weeks after the
baseline time point, the patient could sit on the bed for a
few minutes.
Six months later, she had total recovery of the involun-
tary movements of the face, mouth, extremities, and
trunk, but she still experienced the neurological sequelae
of general weakness and dysarthria. Muscle power assess-
ment revealed movement possible against gravity but
without imposed resistance. As shown in Table 1, facial and
oral involuntary movements showed early improvement 6
weeks later, and the improvement rate was lowest in
Category IV of the Abnormal Involuntary Movement Scale
(AIMS) [1], which encompasses the overall severity, the
patient’s awareness of the movements, and the distress
associated with them.
Multiple etiologies may account for the development of
chronic dyskinesia such as antipsychotics, encephalitis, a
stroke involving the brainstem, nonketotic hyperglycemia,
hepatocerebral degeneration, and hypoxic encephalopa-
thy. In our patient, the aforementioned causes were
excluded by the clinical evaluation.
Second-generation antipsychotics are reportedly less
likely to induce extrapyramidal syndrome [2]. Therefore,
we restored quetiapine therapy for maintenance treat-
ment. The involuntary movement continued to improve
during the period she used quetiapine. Quetiapine-
induced involuntary movement was unlikely. Therefore,
we believe that the patient’s dyskinesia was related to
lithium intoxication. Lithium treatment could reduce
glutamate excitotoxicity in neurons and reveal a neuro-
protective effect [3]. By contrast, at a toxic level, lithium
may inhibit glutamate metabolism and allow excitotox-
icity effects in the neurons in the striatum and cortex [4].by Elsevier Taiwan LLC. This is an open access article under the
4.0/).
Table 1 Abnormal Involuntary Movement Scale scores and improvement in a patient with lithium intoxication.
Baselinea Baseline þ 6 wks Baseline þ 12 wks Baseline þ 24 wks
Medications Amantadine (100 mg daily),
clonazepam (1.0 mg daily),









AIMS (categories I to III)
I. Facial and oral movement 13 6 (53.8%) 5 (61.5%) 0 (100%)
II. Extremity movements 7 5 (28.6%) 4 (42.9%) 0 (100%)
III. Trunk movements 3 2 (33.3%) 1 (66.7%) 0 (100%)
Total score of I to III 23 13 (43.5%) 10 (56.5%) 0 (100%)
Global judgmentb 12 9 (25%) 7 (41.7%) 4 (66.7%)
AIMS Z Abnormal Involuntary Movement Scale.
The data are presented as the number or as the number (% improvement rate in the scores).
a The baseline is at 4 weeks after admission. We began to prescribe medications for dyskinesia.
b Category IV of the AIMS scale encompasses the overall severity, the patient’s awareness of themovements, and the distress associated
with the movements.
Letter to the Editor 279Glutamate excitotoxicity may increase cell ion perme-
ability and lead to intracellular calcium overload, which is
crucial for secondary axonal injury. Axonal injury may be
caused by primary axotomy from mechanical forces and
from secondary axotomy due to a series of biochemical
events [5]. In our patient, although there was no evidence
of trauma, a head injury may have occurred when her
conscious was disturbed. However, based on the clinical
findings, axonal injury in the patient can still be explained
by lithium poisoning (i.e., a secondary cause) rather than
by the primary causes of axonal injury. This injury in-
dicates the consequences of decreased brain-derived
neurotrophic factor axonal transport, diminished neuro-
trophic support of the striatum and cortex cells, and
autophagy deficits by impaired axonal transport of auto-
phagosomes. Moreover, a lower dose of lithium inhibits
inositol monophosphatase, which induces autophagy;
however, a higher dose inhibits glycogen synthase kinase-
3b, which suppresses autophagy. Therefore, acute lithium
intoxication in our patient could promote inositol mono-
phosphatase activity and inhibit glycogen synthase kinase-
3b to suppress autophagy [3]. We suggest that an older age
may also explain the prolonged involuntary movement
complication in this patient [2].References
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